Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
Recommendations for pharmacy school graduates, and nice reminders for everyone else.
Health-system pharmacists must not forget the importance of a strong working relationship with nurses.
A pharmacy professor is using her unique skin condition to teach students about drug molecules.
David Nau, PhD, RPh, FAPhA, president of Pharmacy Quality Solutions, talks about how Electronic Quality Improvement Platform for Plans and Pharmacies has helped pharmacists.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$